AstraZeneca ( (GB:AZN) ) has shared an announcement.

Interim data also suggested a strong trend toward improved PFS and OS when evaluating the STRIDE regimen in combination with TACE vs TACE alone.

AstraZeneca (AZN) announced on Thursday that a combination regimen containing its antitumor agent, Imfinzi, was successful in a late-stage trial for a subset of patients with hepatocellular carcinoma, ...

Orphan Drug Designation is a key incentive established by the EMA to facilitate the development and authorisation of ...

Using a custom AI system, researchers identified chemical compounds that show early promise against two conditions that lack effective treatments: hepatocellular carcinoma, the most aggressive form of ...

Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...

April 2 (Reuters) - AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant ...

AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...

The metabolic environment therefore determines the role of this protein in the development of liver cancer: without steatosis, ERMP1 has no influence on tumour development . It is only when the liver ...

The American Cancer Society just awarded a grant to Dr. Trang VoPham to investigate whether the most common form of liver ...